Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Waters Shares Surge on Bullish Analyst Initiation

Robert Sasse by Robert Sasse
October 9, 2025
in Analysis, Industrial, Pharma & Biotech
0
Waters Stock
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Waters Corporation witnessed a significant uptick in its stock price yesterday, climbing 3.3% to close at $328.73. This notable advance was primarily fueled by Rothschild Redburn, which commenced coverage of the company with a highly optimistic “Buy” recommendation. The financial services firm set a price target of $390 for the shares, indicating substantial potential upside from current levels.

Strong Fundamentals Underpin Positive Outlook

The company’s robust financial health provides a solid foundation for this bullish sentiment. For the second quarter of 2025, Waters reported revenue of $771 million, exceeding market expectations and delivering an 8% increase in earnings. The firm’s gross margin stood at an impressive 59.02%, highlighting its operational efficiency and pricing power within the sector.

Rothschild Redburn’s analysis emphasized Waters’ position as the premier pure-play provider in analytical instruments, noting its industry-leading EBITA margins of 31%. A key strength identified was the company’s recurring revenue model, with approximately 60% of sales originating from services and consumables dedicated to the pharmaceutical industry.

Strategic Acquisition Reshapes Market Position

A transformative development for Waters is its planned acquisition of Becton Dickinson’s biosciences and diagnostics division, valued at $17.5 billion. Market experts view this transaction as a potential game-changer that will effectively double the company’s addressable market to an estimated $40 billion. This expanded market is projected to grow at an annual rate of 5-7%, providing significant long-term growth opportunities.

Should investors sell immediately? Or is it worth buying Waters?

The acquisition process is expected to conclude in early 2026, positioning the combined entity as a dominant force in the life sciences sector. According to Rothschild Redburn’s projections, the merged company could achieve annual EPS growth of 14% through 2029.

Divergent Views Create Market Uncertainty

While Rothschild Redburn expresses strong conviction, the broader analyst community presents a more varied perspective. Weiss Ratings simultaneously reaffirmed its “Hold” rating on Waters shares. Other financial institutions, including Stifel and KeyBanc, maintain positions ranging from “Hold” to “Overweight,” reflecting differing assessments of how the acquisition will impact the company’s future performance.

Market participants are looking toward November 4th for greater clarity, when Waters is scheduled to release its quarterly earnings. This upcoming report could determine whether the stock maintains its upward trajectory or faces a corrective phase, making the current trading environment particularly significant for investors monitoring this evolving situation.

Ad

Waters Stock: Buy or Sell?! New Waters Analysis from January 11 delivers the answer:

The latest Waters figures speak for themselves: Urgent action needed for Waters investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from January 11.

Waters: Buy or sell? Read more here...

Tags: Waters
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Viking Therapeutics Stock
Analysis

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

January 11, 2026
Astera Labs Stock
Analysis

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

January 11, 2026
Realty Income Stock
Analysis

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

January 11, 2026
Next Post
Thermo Fisher Scientific Stock

Thermo Fisher's Diagnostic Breakthrough Could Reverse Stock Fortunes

Mastercard Stock

Mastercard Doubles Down on Digital Growth and AI Security

Beyond Meat Stock

Plant-Based Pioneer Faces Regulatory and Financial Crossroads

Recommended

Transportation Stock Bull Market

JR Kyushu Implements AIPowered AMD Kria K26 SOM for Enhanced Track Inspection Efficiency and Safety

2 years ago
TMUS stock news

Wedbush Analyst Maintains Outperform Rating and Raises Price Target for Global Payments

2 years ago
JD.com Stock

JD.com Shares Surge on Robust Performance and Strategic Moves

3 months ago
Mobile-handsets

Palantir Technologies Reveals Revenue Projections for Q1 2024

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Procter & Gamble Shares Approach a Critical Juncture

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

Palantir Shares: A Wall Street Divide and a Bold New Price Target

Nvidia Accelerates AI Dominance with Early Chip Launch and Strategic Expansions

Netflix Shares Under Pressure Amid High-Stakes Acquisition Battle

Marvell Technology Shares Face Conflicting Market Cues

Trending

Viking Therapeutics Stock
Analysis

Viking Therapeutics: A Tale of Clinical Progress and Insider Selling

by Felix Baarz
January 11, 2026
0

The shares of Viking Therapeutics, a biotechnology firm, are presenting investors with a conflicting narrative this week....

Astera Labs Stock

Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals

January 11, 2026
Realty Income Stock

Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

January 11, 2026
Procter & Gamble Stock

Procter & Gamble Shares Approach a Critical Juncture

January 11, 2026
Vital Farms Stock

Vital Farms Shares Face Headwinds Amid Forecast Revisions and Insider Activity

January 11, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Viking Therapeutics: A Tale of Clinical Progress and Insider Selling
  • Astera Labs Shares Face Selling Pressure Amid Strong Fundamentals
  • Institutional Investors Increase Stakes in Realty Income Amid Strategic Refinancing

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com